1887

Abstract

Possible human infection with simian virus 40 (SV40) has been of great concern ever since SV40 was discovered in polio vaccines. Human populations are SV40-seropositive, but because of serological cross-reactivity between SV40 and the human polyomaviruses BK virus (BKV) and JC virus (JCV), it is debatable whether these antibodies are specific. An SV40-specific serological assay was established, based on purified virus-like particles (VLPs), where the SV40 VLPs were blocked with hyperimmune sera to BKV and JCV. Competition with SV40 hyperimmune sera was used as a confirmatory test. Among 288 Swedish children of between 1 and 13 years of age, 7·6 % had SV40-specific antibodies. SV40 seroprevalence reached a peak of 14 % at 7–9 years of age. Among 100 control patients with benign tumours, 9 % were SV40-seropositive. However, SV40 DNA was not detectable in corresponding buffy-coat samples. In serial samples taken up to 5 years apart from 141 Finnish women participating in the population-based serological screening for congenital infections, only two of 141 women were SV40-seropositive in both samples. Six women seroconverted and eight women had a loss of antibodies over time. None of the SV40-seropositive samples contained detectable SV40 DNA. In conclusion, there is a low prevalence of SV40-specific antibodies in the Nordic population. The SV40 antibodies appear to have a low stability over time and their origin is not clear.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80783-0
2005-06-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861703.html?itemId=/content/journal/jgv/10.1099/vir.0.80783-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. & Dillner, J. ( 1998; ). Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177, 1710–1714.[CrossRef]
    [Google Scholar]
  2. af Geijersstam, V., Eklund, C., Wang, Z., Sapp, M., Schiller, J. T., Dillner, J. & Dillner, L. ( 1999; ). A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 80, 489–493.[CrossRef]
    [Google Scholar]
  3. Bergsagel, D. J., Finegold, M. J., Butel, J. S., Kupsky, W. J. & Garcea, R. L. ( 1992; ). DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 326, 988–993.[CrossRef]
    [Google Scholar]
  4. Butel, J. S. & Lednicky, J. A. ( 1999; ). Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91, 119–134.[CrossRef]
    [Google Scholar]
  5. Carter, J. J., Madeleine, M. M., Wipf, G. C., Garcea, R. L., Pipkin, P. A., Minor, P. D. & Galloway, D. A. ( 2003; ). Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95, 1522–1530.[CrossRef]
    [Google Scholar]
  6. Christensen, N. D., Reed, C. A., Cladel, N. M., Han, R. & Kreider, J. W. ( 1996; ). Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70, 960–965.
    [Google Scholar]
  7. Dillner, L., Heino, P., Moreno-Lopez, J. & Dillner, J. ( 1991; ). Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol 65, 6862–6871.
    [Google Scholar]
  8. Engels, E. A., Viscidi, R. P., Galloway, D. A. & 8 other authors ( 2004; ). Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 96, 1368–1374.[CrossRef]
    [Google Scholar]
  9. Gedvilaite, A., Frommel, C., Sasnauskas, K. & 7 other authors ( 2000; ). Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273, 21–35.[CrossRef]
    [Google Scholar]
  10. Heid, C. A., Stevens, J., Livak, K. J. & Williams, P. M. ( 1996; ). Real time quantitative PCR. Genome Res 6, 986–994.[CrossRef]
    [Google Scholar]
  11. Hilleman, M. R. ( 1998; ). Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand 94, 183–190.
    [Google Scholar]
  12. Knowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G. & Miller, E. ( 2003; ). Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71, 115–123.[CrossRef]
    [Google Scholar]
  13. Minor, P., Pipkin, P., Jarzebek, Z. & Knowles, W. ( 2003; ). Studies of neutralising antibodies to SV40 in human sera. J Med Virol 70, 490–495.[CrossRef]
    [Google Scholar]
  14. Olin, P. & Giesecke, J. ( 1998; ). Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 94, 227–233.
    [Google Scholar]
  15. Rector, A., Tachezy, R. & Van Ranst, M. ( 2004; ). A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification. J Virol 78, 4993–4998.[CrossRef]
    [Google Scholar]
  16. Sasnauskas, K., Buzaite, O., Vogel, F., Jandrig, B., Razanskas, R., Staniulis, J., Scherneck, S., Kruger, D. H. & Ulrich, R. ( 1999; ). Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 380, 381–386.
    [Google Scholar]
  17. Shah, K. V. ( 2000; ). Does SV40 infection contribute to the development of human cancers? Rev Med Virol 10, 31–43.[CrossRef]
    [Google Scholar]
  18. Stolt, A., Sasnauskas, K., Koskela, P., Lehtinen, M. & Dillner, J. ( 2003; ). Seroepidemiology of the human polyomaviruses. J Gen Virol 84, 1499–1504.[CrossRef]
    [Google Scholar]
  19. Stolt, A., Kjellin, M., Sasnauskas, K., Luostarinen, T., Koskela, P., Lehtinen, M. & Dillner, J. ( 2005; ). Maternal human polyomavirus infection and risk of neuroblastoma in the child. Int J Cancer 113, 393–396.[CrossRef]
    [Google Scholar]
  20. Strickler, H. D. & Goedert, J. J. ( 1998; ). Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer – a review of the epidemiological evidence. Dev Biol Stand 94, 235–244.
    [Google Scholar]
  21. Sweet, B. H. & Hilleman, M. R. ( 1960; ). The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 105, 420–427.[CrossRef]
    [Google Scholar]
  22. Tedeschi, R., Enbom, M., Bidoli, E., Linde, A., De Paoli, P. & Dillner, J. ( 2001; ). Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 39, 4269–4273.[CrossRef]
    [Google Scholar]
  23. Vilchez, R. A., Kozinetz, C. A. & Butel, J. S. ( 2003; ). Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 4, 188–191.[CrossRef]
    [Google Scholar]
  24. Viscidi, R. P., Rollison, D. E. M., Viscidi, E., Clayman, B., Rubalcaba, E., Daniel, R., Major, E. O. & Shah, K. V. ( 2003; ). Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10, 278–285.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80783-0
Loading
/content/journal/jgv/10.1099/vir.0.80783-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error